【摘要】 目的比较重组型纤溶酶原激活剂(rt-PA)和尿激酶(UK)对急性心肌梗死(AMI)溶栓的效果和不良反应。方法对我院AMI接受溶栓治疗患者回顾性分析,每组各30例,一组予70～100 mg rt-PA溶栓,另一组予150万U UK溶栓治疗,统计两组溶栓再通率、不良反应发生率。其中48例择期行冠脉造影,以判定冠脉是否再通,同时与临床再通的指标进行比较。结果溶栓再通率rt-PA组为86．7%,UK组为63．3%,两组比较有统计学意义(P＜0．05)；不良反应两组比较无统计学意义(P＞0．05)；临床再通率与造影再通率正相关(r=0．90)。结论溶栓再通率rt-PA高于UK；判断临床再通率与造影再通率差异无统计学意义(P＞0．05),在没有冠脉造影的条件下,临床指标仍然是判定冠脉再通的有效指征。更多还原

【Abstract】 Objective To observe and compare the clinical efficacy and adverse reaction of recombinant tissue -type plas- minogen activator (rt-PA) and urokinase (UK) in acute myocardial infarction (AMI).Methods 60 AMI patients with thrombolytic therapy were retrospectively analyzed.30 patients were treated by rt-PA (70～100 mg) and the others were treated by UK (1.5 MU).Percentage of reperfusion,mortality and adverse reaction rate were recorded.Coronary angiography was carried out and compared with clinical indexes for evaluating coronary recanalization.Results The reperfusion rate of rt - PA group was 86.7% and UK group 63.3% (P＜0.05) respectively.There were no significant differences in adverse,reaction between rt - PA group and UK group (P＞0.05).Rate of coronary recanalization evaluated by clinical indexes and that evaluated by coronary angiography were positive correla- tion (r=0.90).Conclusion The reperfusion rate in rt - PA group is higher than that in UK.There were no significant differences between the reperfusion rate of clinical and that of coronary angiography(P＞0.05).The clinical indexes are still valid for estimating coronary reperfusion without coronary angiography.更多还原